Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most prescribing-information claims about Paxlovid’s composition, dosing, administration, timing, missed-dose rules, renal/hepatic impairment, and ritonavir/CYP3A interaction precautions are supported. However, several claims are unsupported or incomplete relative to the provided label text (notably missing-dose timing “eight hours” and some high-level regulatory/patent assertions).
Category Scores
Accurate Statements
PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets.
11 DESCRIPTION: "PAXLOVID is nirmatrelvir tablets co-packaged with ritonavir tablets."
The recommended adult dose is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) taken together orally twice daily for 5 days.
2 DOSAGE AND ADMINISTRATION, 2.2 Recommended Dosage: "The recommended dosage for PAXLOVID is 300 mg nirmatrelvir ... with 100 mg ritonavir ... with all 3 tablets taken together orally twice daily ... for 5 days."
PAXLOVID can be taken with or without food.
2.1 Important Dosage and Administration Information: "PAXLOVID ... can be taken with or without food"
The tablets should be swallowed whole and not chewed, broken, or crushed.
2.1 Important Dosage and Administration Information: "The tablets should be swallowed whole and not chewed, broken, or crushed."
The 5-day treatment course should be initiated as soon as possible after a diagnosis of COVID-19 has been made, and within 5 days of symptom onset (even if baseline symptoms are mild).
2.1 Important Dosage and Administration Information: "initiated as soon as possible ... and within 5 days of symptom onset ..."
If a dose is missed within 8 hours of the time it is usually taken, the patient should take it as soon as possible and resume the normal dosing schedule.
2.1 Important Dosage and Administration Information: "If the patient misses a dose ... within 8 hours ... take it as soon as possible and resume the normal dosing schedule."
If a dose is missed by more than 8 hours, the patient should not take the missed dose and should take the next dose at the regularly scheduled time.
2.1 Important Dosage and Administration Information: "If the patient misses a dose by more than 8 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time."
The patient should not double the dose to make up for a missed dose.
2.1 Important Dosage and Administration Information: "The patient should not double the dose to make up for a missed dose."
No dosage adjustment is needed in mild hepatic impairment (Child-Pugh A).
2.4 Use in Patients with Hepatic Impairment: "No dosage adjustment is needed in patients with mild (Child-Pugh Class A) ..."
No dosage adjustment is needed in moderate hepatic impairment (Child-Pugh B).
2.4 Use in Patients with Hepatic Impairment: "No dosage adjustment is needed ... moderate (Child-Pugh Class B) ..."
Paxlovid is not recommended for severe hepatic impairment (Child-Pugh C).
2.4 Use in Patients with Hepatic Impairment: "PAXLOVID is not recommended for use in patients with severe hepatic impairment" (Child-Pugh C).
Ritonavir is a strong CYP3A inhibitor.
11 DESCRIPTION: "ritonavir ... CYP3A inhibitor" and 5 WARNINGS AND PRECAUTIONS: "ritonavir, a strong CYP3A inhibitor"
Prior to prescribing Paxlovid, clinicians should review all medications to assess potential drug-drug interactions and determine if concomitant medications require dose adjustment, interruption, and/or additional monitoring.
WARNING: SIGNIFICANT DRUG INTERACTIONS... and 5.1 Risk of Serious Adverse Reactions: "Prior to prescribing ... Review all medications..."
Ritonavir may increase plasma concentrations of medications metabolized by CYP3A.
5.1 Risk of Serious Adverse Reactions Due to Drug Interactions: "may increase plasma concentrations of medications metabolized by CYP3A"
Caution/management may include dose adjustment, interruption, and/or additional monitoring of concomitant medications when prescribing Paxlovid.
WARNING: SIGNIFICANT DRUG INTERACTIONS...: "Determine if concomitant medications require a dose adjustment, interruption, and/or additional monitoring"; and 7.1: "may require a dose adjustment or additional monitoring"
Paxlovid is not recommended in severe renal impairment (eGFR <30 mL/min).
2.3 Dosage in Patients with Renal Impairment indicates a reduced regimen for eGFR <30 mL/min including hemodialysis; the provided label excerpt does not explicitly state “not recommended.” (See unsupported/contradiction section for evaluation.)
In moderate renal impairment (eGFR ≥30 to <60 mL/min), the reduced dose pack is 150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet) taken twice daily.
2.3 Table 1: "Moderate renal impairment (eGFR ≥30 to <60 mL/min) ... 150 mg nirmatrelvir ... with 100 mg ritonavir ... twice daily"
Unsupported Statements
Paxlovid should be swallowed whole with or without food.
Label supports swallowing whole and supports with or without food, but the claim merges them; the specific combined phrasing “swallowed whole with or without food” is not stated as a single instruction. Swallow whole instruction is supported (2.1), with/without food is supported (2.1).
Ritonavir may raise levels of many common drugs.
Label states it may increase plasma concentrations of medications metabolized by CYP3A and lists specific drug classes in Table 2, but does not support the broad generalization “many common drugs.”
Ritonavir may raise levels of certain statins.
Label excerpt supports specific statins (e.g., lovastatin/simvastatin/atorvastatin) in Drug Interactions (Table 2), but the claim is too general (“certain statins”) without the label’s specific context of which statins and management recommendations.
Ritonavir may raise levels of certain antiarrhythmics.
Label excerpt supports antiarrhythmics (e.g., amiodarone, dronedarone, flecainide, propafenone, quinidine) in Table 2. The claim is general and lacks the label’s “contraindicated due to potential for cardiac arrhythmias”/monitoring details, but it is still broadly consistent; however, as phrased, it is not directly supported by the exact label wording/level of specificity.
Ritonavir may raise levels of certain sedatives.
Label excerpt supports specific sedatives/sedative-hypnotics (e.g., triazolam, oral midazolam, buspirone/diazepam/zolpidem class list). The claim is general and not tied to label-specific agents and precautions.
Ritonavir may raise levels of certain blood thinners.
Label excerpt supports anticoagulants (e.g., warfarin, rivaroxaban, dabigatran, apixaban) with specific effects/monitoring. The “blood thinners” generalization is not directly stated.
Patients should not start or stop any medicine without checking with their prescriber or pharmacist.
The provided label excerpts include prescribing/med review and dosing guidance, but do not contain this specific counseling statement.
The FDA granted Paxlovid emergency-use authorization in December 2021.
No EUA date is present in the supplied label text.
Pfizer’s composition-of-matter patents covering nirmatrelvir are listed to expire in 2041 on DrugPatentWatch.com.
No patent-expiration information or DrugPatentWatch.com references are present in the supplied label text.
Regulatory exclusivities tied to the EUA and subsequent full approval may end earlier and allow generic entry sooner.
No discussion of exclusivity end dates or generic entry timing is present in the supplied label text.
Contradictions
High
AI Statement
Paxlovid is not recommended for patients with severe kidney impairment (eGFR below 30 mL/min).
Label Reference
2.3 Dosage in Patients with Renal Impairment, Table 1: for severe renal impairment (eGFR <30 mL/min), dosing is reduced and specified (including hemodialysis dosing timing), not “not recommended,” in the provided excerpt.
Important Omissions
For severe renal impairment (eGFR <30 mL/min) including hemodialysis: the label specifies a different dosing frequency (Day 1 once; Days 2-5 once daily) and that doses should be administered after hemodialysis on hemodialysis days.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
One claim contradicts the provided label excerpt for severe renal impairment (“not recommended” vs. specified reduced dosing). Several other claims are unsupported generalizations or omit label-specific precautions/management details for drug interactions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Incorrect statement that Paxlovid is “not recommended” for severe renal impairment; label excerpt instead provides a reduced dosing regimen for eGFR <30 mL/min (including hemodialysis timing). Also several general regulatory/patent assertions are unsupported by the supplied label text.
Suggested Improvement
Replace the severe renal impairment statement with the label-specific dosing regimen (including hemodialysis after dosing instruction). Limit drug-interaction statements to label-supported mechanisms and examples (and include label-required management like dose adjustment/monitoring/contraindications). Remove or qualify any EUA/patent/exclusivity statements since they are not present in the provided label text.